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Background. The aim of this study was to assess feasi-
bility and efficacy of weekly concomitant boost accelerated
postoperative radiation therapy (PORT) with concomitant
chemotherapy (CT) in patients with locally advanced head
and neck cancer (LAHNC).
Methods and Materials. Conformal or intensity-modu-
lated 66-Gy RT was performed in 5.5 weeks in 40 patients.
Cisplatin was given at days 1, 22, and 43. Median follow-
up was 36 months.
Results and Discussion. Grade 3 mucositis, dysphagia,
and erythema was observed in ten (25%), nine (23%), and
six (13%) patients, respectively. Grade 3 or more anemia
was observed in two (6%) patients, and leukopenia in five
(13%) patients. No grade 3 or 4 thrombocytopenia was
observed. Grade 3 nephrotoxicity was observed in one
patient (3%). No treatment-related mortality was observed.
Grade 2 or more xerostomia and edema were observed in
ten (25%) and one (3%) patient, respectively. Locoregional
relapse occurred in eight patients, and seven patients
developed distant metastases. Median time to locoregional
relapse was 6 months. Three-year overall, disease-free
survival, and locoregional control rates were 63%, 62%,
and 81%, respectively. Multivariate analysis revealed that
the only prognostic factor was nodal status.
Conclusion. Reducing overall treatment time using
accelerated PORT/CT by weekly concomitant boost (six
fractions per week) combined with concomitant cisplatin
CT is easily feasible with acceptable morbidity.
Following surgery, postoperative radiotherapy (RT)
combined with concomitant chemotherapy (CT) improves
the outcome in locally advanced head and neck cancer
(LAHNC).1,2 Despite multimodality treatment, locore-
gional relapse risk remains as high as 35–40%.3–5 The risk
of recurrence or metastasis is particularly high in patients
with inadequate resection margins, extranodal spread or
multiple involved lymph nodes.6 Various strategies have
been proposed to improve the outcome.7–10 Two major
approaches have gained importance in recent years to
improve the outcomes: altered fractionation and concomi-
tant CT regimens. Confirming expectations based on
radiobiological theory, altered fractionation regimens could
overcome accelerated tumor population, and concurrent
delivery of CT and ionizing radiation could sensitize tumor
clonogens.
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Data concerning hyperfractionated or accelerated RT with
concomitant CT are very limited, and there are no prospective
data in the postoperative setting. We previously showed the
feasibility of accelerated (six fractions/week) fractionated
66-Gy postoperativer RT (PORT) using a single-fraction
regimen from Monday to Thursday and a concomitant boost
(two fractions separated by 6-h interval) at Friday afternoon
sessions with acceptable toxicity.11 On the basis of these
findings, in this study we combined concomitant cisplatin CT
to accelerated PORT in patients with LAHNC in order to
increase locoregional control (LRC) and survival.
METHODS AND MATERIALS
Forty consecutive patients with advanced-stage squa-
mous-cell carcinoma of head and neck treated at the
University Hospital of Lausanne (CHUV) were included in
this study. All patients were treated with curative surgery
followed by accelerated PORT and concomitant CT.
Inclusion criteria consisted of nonmetastatic LAHNC
classified as pT1–pT4 and/or pN0–pN3, age 18 years or
older, no previous history of cancer other than nonmel-
anoma skin cancer or in situ cervix cancer, and good
performance status [World Health Organization (WHO)
scale 0–1]. The study was approved by the Ethical Com-
mittee of the University of Lausanne. T- and N-
classification were assigned according to the staging sys-
tem of the International Union against Cancer (UICC)
2002.12 Pretreatment characteristics are listed in Table 1.
Pretreatment evaluation included a medical history,
examination with panendoscopy (oro-pharyngo-laryngos-
copy, bronchoscopy, and esophagoscopy), and computed
tomography and/or magnetic resonance imaging (MRI) of
the head and neck region in all cases. Additional diagnostic
procedures for distant metastases, including computed
tomography of the chest, liver ultrasound, bone scintigra-
phy, and/or more recently positron emission tomography,
were only performed if clinically indicated. Laboratory
studies included blood chemistry (electrolytes, liver and
kidney function tests), and complete blood count were
performed each week of the treatment.
All patients were seen and discussed at our multidisci-
plinary tumor board, and the treatment recommendation
was made jointly by head and neck surgeons, radiation
oncologists, and medical oncologists with advice from the
diagnostic radiologist, pathologist, nuclear medicine spe-
cialist, nursing staff, nutritionists, and dentists.
Percutaneous endoscopic gastrostomy (PEG) was placed
before or at the beginning of treatment in 17 of the 40 (43%)
patients, and 4 patients (10%) had nasogastric feeding tube
on the basis of our previous experience.13 Nutritional
intervention, professional surveillance, advice, and support
were available during the entire treatment period; prophy-
lactic mouth washes were recommended, and fungal or
bacterial infections on mucous membranes were treated
according to microbiologic testing. All patients had dental
examination and, if necessary, dental treatment before start
of treatment.
Postoperative Treatment
Postoperative accelerated 66-Gy RT was given using six
fractions per week (2 Gy/fraction) with a single-fraction
regimen from Monday to Thursday and a two fractions
including a concomitant boost on Friday (with an interval
of at least 6 h) during 5.5 weeks (38 days). RT was
implemented in all patients using five-field three-dimen-
sional (3D) conformal or intensity-modulated RT (IMRT),
according to the Groupe Oncologie-Radiothe´rapie Teˆte et
Cou (GORTEC)/European Organisation for Research and
Treatment of Cancer (EORTC)/Radiation Therapy Oncol-
ogy Group (RTOG) guidelines. The boost volume (66 Gy)
TABLE 1 Patient characteristics
Number %
Tumor site
Oral cavity 15 38
Oropharynx 8 20
Hypopharynx 8 20
Larynx 7 18
Unknown primary 2 5
RT indications
Extranodal infiltration: 24 60
With (?) surgical margin 13 32
Without (?) surgical margin 11 28
Without extranodal infiltration 16 40
(?) surgical margin 9 22
T4 tumors 5 13
C3 lymph nodes 2 5
pT-classification
0 2 5
1 5 12
2 16 40
3 2 5
4 15 38
pN-classification
0 3 7
1 8 20
2a 2 5
2b 15 38
2c 5 12
3 7 18
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consisted of the clinical target volume (CTV1), which was
defined according to the presurgical location of the primary
tumor, and its nodal extension including the entire surgical
bed. Planning target volume (PTV1) included a 5-mm
margin around the CTV1 in three dimensions. The initial
treatment volume (PTV2, 46–50 Gy) consisted of the boost
volume and all nodal areas at risk of subclinical malignant
disease (PTV2), including a 5-mm margin around the
CTV2 in three dimensions. Patient immobilization was
realized using individualized thermoplastic immobilization
masks in all patients.
Concomitant cisplatin CT was planned at 100 mg/m2 at
days 1, 22, and 43 in all but five patients, in whom car-
boplatin [area under the curve (AUC) = 2 weekly, or
AUC = 5 days 1, 22, and 43] was chosen due to inade-
quate renal function.
Patients received prophylactic hydration and antiemetic
agents and were seen weekly by the radiation oncologist,
head and neck surgeon, and/or medical oncologist during
RT. Special advice and attention were given by the nursing
team to skin care, and oral hygiene was enforced. Symp-
tomatic treatment for mucositis (sodium bicarbonate) was
offered, and oral candidiasis was promptly treated by
fluconazol.
Toxicity Assessment and Follow-Up
Toxicity assesment was done according to the Common
Toxicity Criteria (CTC)/National Cancer Institute (NCI)
v3.0. Patients were not assessed by the same observer.
Clinical examination and toxicity assessment was repeated
weekly during RT. Patients were then followed by the head
and neck surgeon and radiation oncologist weekly during
the first 2 months, monthly assessments from 2–6 months,
and every 2–3 months until 2 years. At that time, a pan-
endoscopy was performed, and MRI, computed
tomography, and biopsies were performed as indicated.
Patients without evidence of disease were subsequently
followed every 6 months up to 5 years, then once per year.
Statistical Methods
Cause-specific survival (CSS), disease-free survival
(DFS), and overall survival (OS) rates as well as actuarial
LRC rates were calculated using product-limit method.14
Time to any event was measured from the date of patho-
logical diagnosis. The events were death (all causes) for
OS, head and neck cancer-related mortality for CSS, and
death (all causes) or relapse for DFS. For the LRC rate, the
event consisted of local or regional relapse. Confidence
intervals (CI) were calculated from standard errors. Dif-
ferences between groups were assessed using the log-rank
test.15 Multivariate analyses were done using the Cox
stepwise-regression analysis to determine the independent
contribution of each prognostic factor.16
RESULTS
Between March 2001 and April 2006, 36 men and 4
women with pT1–pT4 and/or pN0–pN3 LAHNC were
included in this study. Median age was 60 years (range 36–
81 years). Indications of PORT/CT were positive surgical
margins (n = 9; all R1), T4 R0 tumors (n = 5), three or
more positive lymph nodes without extranodal infiltration
(all R0; n = 2) in 16 (40%) patients; or extranodal infil-
tration with (all R1; n = 13) or without (n = 11) positive
surgical margins in 24 (60%) patients. Twenty-three
patients with T0 (n = 2), T1 (n = 5), and T2 (n = 16)
were included because of positive surgical margins (n = 4;
all R1) or because of advanced nodal disease.
Median interval between surgery and RT was 46 days
(range 24–112 days), and median RT duration was 39 days
(range 35–62 days). In five patients, treatment duration was
longer than 45 days because of toxicity. All but two
patients received the planned total dose without unplanned
interruption (66 Gy in 38, 64 Gy in 1, and 58 Gy in 1).
Three cycles of planned full-dose cisplatin could be
administered in 18 patients (54%). Because of toxicity, 15
patients (43%) could receive only two cycles of CT, and 2
patients only (3%) one cycle of CT. Dose reduction of
cisplatin was necessary in two patients, who could receive
only two cycles of CT. Carboplatin was given weekly in
one patient, and every 3 weeks in four patients.
Three patients had local relapse only, one patient loco-
regional relapse, two patients regional relapse alone, two
patients regional relapse and distant metastases, and five
patients had only distant metastases (Fig. 1). Median time
to locoregional relapse was 6 months (range 1–40 months).
Three-year OS, CSS, DFS, and LRC rates were 63% (95%
CI 46–78%), 66% (95% CI 50–82%), 62% (95% CI 48–
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FIG. 1 Distribution of relapses in 40 patients treated with acceler-
ated weekly concomitant boost postoperative radiation therapy
combined with concomitant chemotherapy
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78%), and 81% (95% CI: 69–93%), respectively (Fig. 2).
Distant metastasis probability at 3 years was 20% (95% CI
7–33%). For univariate analyses gender, age, tumor site,
pT- classification, pN-classification, extracapsular nodal
extension, positive surgical margins, interval between
surgery and RT, and total RT time were analyzed
(Table 2). Univariate and multivariate analyses revealed
that the only prognostic factor influencing the outcome was
nodal status, for both DFS and LRC [relative risk
(RR) = 0.40, P = 0.02; and RR = 0.0004, P = 0.02].
Incidence of grade 3 mucositis was 25% (n = 10), grade
3 dysphagia 23% (n = 9), and grade 3 skin erythema 13%
(n = 5). CT-related anemia was observed in two patients
(grade 3 in one, and grade 4 in one), leukopenia in four
patients (grade 3 in two, and grade 4 in two), and no grade
3 or 4 thrombopenia was observed. Grade 3 renal toxicity
was observed in only one patient (Table 3). Median weight
loss was 3.5 kg (range 0–14.5 kg). No treatment-related
mortality was observed.
Considering late effects, grade 0, 1, 2 or 3 xerostomia
was observed in 9 (23%), 22 (55%), 9 (23%), and 1 (3%)
patient, respectively; grade 0, 1, and 2 edema was observed
in 25 (63%), 14 (35%), and 1 (3%) patient, respectively.
Two patients developed mandibular osteoradionecrosis.
DISCUSSION
The impact of shortening overall treatment time on
therapeutic outcome is well established. Several studies
validated that, compared with conventional fractionation
using 2 Gy per day, altered fractionation (especially hy-
perfractionated or accelerated RT) increases locoregional
tumor control in patients with HNSCC.9,17–19 Ang et al.
compared an accelerated concomitant boost PORT deliv-
ering a total dose of 63 Gy in 35 fractions of 1.8 Gy during
5 weeks (five fractions/week during 3 weeks and two
fractions/day during 2 weeks) with a conventionally frac-
tionated PORT delivering a total dose of 63 Gy in 35
fractions of 1.8 Gy/fraction during 7 weeks.20 This study,
in the accelerated PORT arm, showed higher but not sta-
tistically significant improvement in 5-year LRC
(P = 0.11) and OS (P = 0.08) in favor of accelerated arm.
However, it confirmed prospectively that, in patients trea-
ted by conventional fractionation, delay of more than
6 weeks between surgery and RT significantly reduces
LRC and OS. Another important study by Overgaard et al.
compared a modestly accelerated regimen of 66–70 Gy in
2-Gy fractions given six times per week with the same dose
given in five fractions per week, using nimorazole in both
groups.21 They reported a gain of 15% in local control
using accelerated RT, with increased acute toxicity but no
increase in late toxicity. In the postoperative setting, San-
guineti et al. and Swunski et al. confirmed the feasibility of
accelerated PORT.22,23 Like Ang et al., Sanguineti et al.
found that patients delaying the start of RT benefited more
from accelerated RT in terms of LRC; however, they did
not observe any difference between the standard and
accelerated treatment arms (2-year LRC of 80% and 78%,
respectively). Swunski et al. reported acceptable acute
toxicity, in spite of high intensity and duration of mucosal
reactions, in the continous accelerated treatment arm.
The impact of overall treatment time on outcome is
more important for locoregional control than survival.
Overall, the incidence of distant metastases can reach 20–
40%. Several studies have demonstrated that the addition
of CT to RT improves survival. The EORTC and the
RTOG have both recently conducted randomized phase III
trials comparing this approach with standard PORT.1,2 The
EORTC 22931 study showed improved LRC, DFS, and OS
with the combined treatment modality. However, the
RTOG 10-95 study failed to show a significant difference
in terms of OS whereas LRC and DFS were significantly
improved by the combined modality. A combined analysis
of both studies revealed that addition of concomitant che-
motherapy to PORT results in significantly better outcome,
especially in patients with inadequate resection margins
and/or extranodal spread.6
Concomitant CT and hyperfractionated or accelerated
RT without surgery has been confirmed by several studies;
however, there are no data in the postoperative setting.24–28
In our department, accelerated RT has been implemented
since 1998. In our experience, concurrent administration of
three cycles of full-dose cisplatin and 5-fluorouracil (5-FU)
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FIG. 2 Probability of overall survival (solid line), disease-free
survival (dotted line), and locoregional failure (dashed line) in 40
patients treated with accelerated weekly concomitant boost postop-
erative radiation therapy combined with concomitant chemotherapy
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CT and concomitant boost accelerated 70-Gy RT is feasi-
ble in patients with advanced squamous cell carcinoma of
the head and neck.29 We also reported our results using
accelerated PORT, in which 2-year actuarial LRC was
80%, and distant metastases probabilty was 38% with
acceptable toxicity.11 In the present study, we aimed to
assess whether weekly concomitant boost (six fractions per
week) accelerated PORT combined with cisplatin CT is
better than accelerated PORT alone. Three-year OS and
LRC rates were 65% and 82%, respectively; distant
TABLE 3 Acute toxicity
Toxicity Grade I (%) Grade II (%) Grade III (%) Grade IV (%)
Mucositis 11 (28) 19 (47) 10 (25) –
Dysphagia 9 (23) 22 (54) 9 (23) –
Erythema 13 (32) 21 (53) 6 (15) –
Anemia 27 (68) 7 (18) 1 (3) 1 (3)
Leukopenia 7 (18) 3 (8) 2 (5) 2 (5)
Thrombocytopenia 12 (30) – – –
Renal toxicity 10 (25) 2 (5) 1 (3) –
TABLE 2 Univariate analyses
ENE extranodal infiltration
N 3-year 95% CI P-value 3-year 95% CI P-value
DFS LRC
All patients 40 62 48–78 – 81 69–93 –
Gender
Female 4 100 – 0.13 100 – 0.29
Male 36 59 43–75 – 79 65–93 –
Age (years)
\60 20 74 54–94 0.35 90 76–100 0.47
C60 20 53 31–75 – 73 53–93 –
Tumor site
Oral cavity 15 63 38–87 0.97 78 56–100 0.95
Oropharynx 8 63 30–99 – 75 45–100 –
Larynx 7 71 38–104 – 86 61–100 –
Hypopharynx 8 51 11–91 – 86 61–100 –
Unknown primary 2 – – – – – –
T-classification
pT1-2 23 65 46–84 0.85 78 60–96 0.51
pT3-4 17 61 46–86 – 88 72–100 –
N-classification
pN0-1 11 88 64–112 0.04 100 – 0.07
pN2-3 29 55 37–73 – 75 59–91 –
ENE
No 16 66 44–96 0.81 79 68–90 0.96
Yes 24 61 41–79 83 67–99 –
Positive surgical margin
No 18 64 41–97 0.92 76 54–98 0.34
Yes 22 62 41–95 – 85 69–100 –
Surgery–RT interval
B42 days 16 56 32–80 0.47 75 53–97 0.56
[42 days 24 68 48–88 – 86 70–100 –
RT duration
B39 days 21 61 39–83 0.62 80 62–98 0.88
[39 days 19 66 44–88 – 84 66–100 –
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metastases probability at 3 years was 19%. The incidence
of grade 3 mucositis was 25%, grade 3 dysphagia 23%, and
grade 3 skin erythema 13%. CT-related bone marrow
toxicity was observed in six patients (15%), and grade 3
renal function impairment was observed in only one
patient. In this study, 95% of patients received the pre-
scribed full dose of radiation, and only 54% of patients
were able to complete the full cisplatin dose (three cycles)
with moderate toxicity, a finding also observed in the
EORTC and RTOG studies.1,2 In the future, it should be
considered whether or not to continue with this third cycle
of cisplatin. Acceptable toxicity rates in our series are most
likely due to our relatively soft accelerated RT schedule.
Treating the boost volume every Friday afternoon during
the first 5 weeks by using smaller PTVs is easily accepted
by patients as well as the radiotherapy department.
The results of this trial demonstrated that reducing the
overall treatment time using accelerated PORT/CT by
weekly concomitant boost (six fractions per week) combined
with concomitant cisplatin CT is easily feasible with good
locoregional and distant metastases control in curatively
operated patients with LAHNC. However, acute toxicity
remains the main obstacle to wide acceptance of this treat-
ment modality requiring close follow-up and supportive care
by an experienced multidisciplinary team. Current research
strategies will continue to focus on improving the therapeutic
ratio in an attempt to achieve higher rates of both local and
systemic control. New targeted therapy agents with less
toxicity should be investigated, combined with current che-
moradiation regimens.
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